Last week, Novo Nordisk filed a series of lawsuits across the United States, targeting weight loss clinics and medical spas for alleged trademark infringement and false advertising related to its semaglutide products: Ozempic, Wegovy, and Rybelsus. The pharmaceutical company claims these entities have misappropriated its trademarks to market semaglutide-based compounded drugs for weight loss without FDA approval. The legal actions have been taken across various states, with nearly half of the cases filed in Florida and additional suits in Tennessee, Montana, Colorado, Illinois, and Texas.
“We will continue to pursue legal action against those who provide potentially unsafe and ineffective compounded ‘semaglutide’ products and knowingly deceive patients who are seeking treatment, thereby eroding public trust in the safety of FDA-approved medicines,” stated Doug Langa, executive vice president, North America operations and president of Novo Nordisk.
Read more details about the ongoing legal actions here.